Oncología

Resultados: 501
Tipo Título / Nombre Autor(es) Año
Real-World Data on Immune-Checkpoint Inhibitors in Elderly Patients with Advanced Non-Small Cell Lung Cancer: A Retrospective Study Del Corral-Morales J, Ayala-de Miguel C, Quintana-Cortés L, Sánchez-Vegas A, Aranda-Bellido F, González-Santiago S, et al 2025
Transcriptomic Predictors of Survival for Palbociclib + Endocrine Therapy Versus Capecitabine in Aromatase Inhibitor-Resistant Breast Cancer From the GEICAM/2013-02 PEARL Trial Agrawal YN, Fernández-Martínez A, Gil-Gil M, Zielinski C, Ruiz-Borrego M..., González-Santiago S, et al 2025
Molecular and immune profiling of breast cancer from pregnancy to postpartum: Insights into the tumour-immune landscape during breastfeeding from GEICAM EMBARCAM study Peña Enriquez R, Bermejo B..., López de Ceballos MH 2025
Impact of targeted therapies (TT) and immunotherapy (IO) on outcomes in patients (pts) with anaplastic thyroid carcinoma (ATC): International data from the Spanish GETNE registry Hernando J, Nunes T..., Ayala de Miguel P 2025
Remote physiologic and behavioral monitoring to predict early treatment response in metastatic cancer: High-Definition Oncology study (HDOs) preliminary results Paz Arbeizar L, Sauras M..., Santiago González S 2025
Survival outcomes in radioactive iodine-refractory (RAIR) differentiated thyroid cancer (DTC) with BRAF mutation: a real-world study from the Spanish Taskforce for Neuroendocrine and Endocrine Tumors (GETNE) Thyroid Cancer registry García Álvarez A, Hernando J, Martinez Trufero J..., Ayala de Miguel P 2025
Evaluation of the effectiveness and safety of avapritinib in real-world Spanish cases with gastrointestinal stromal tumor and D842V-PDGFRA mutation Núñez Hernández I, Gómez Palmero C, Delgado JR, Nuño A, Sala González MÁ..., Ayala de Miguel P, et al 2025
Treatment Efficacy and Molecular Dynamics of Neoadjuvant Durvalumab and Olaparib in Resectable Urothelial Bladder Cancer: The NEODURVARIB Trial Rodríguez-Moreno JF, de Velasco G, Álvarez-Fernández C, Collado R, Fernández R, Vázquez S, et al 2025
Neoadjuvant durvalumab and olaparib in resectable urothelial bladder cancer- Impact on its molecular profile and efficacy: Neodurvarib trial Rodríguez Moreno JF, Velasco G de, Collado R 2025
Tumores neuroendocrinos Cerrudo Jiménez G 2025